drugset / Trial / NCT00071422

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

NCT00071422

Phase 2 Completed 126 enrolled Exsulin Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 2 diabetes is a disease where the beta cells are unable to meet a person's insulin needs. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to improve the ability to produce insulin in type 2 diabetic patients.

Timeline

Start
2003-10
Primary completion
2004-06
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject INGAP Peptide Peptide 300 mg Subcutaneous
Subject INGAP Peptide Peptide 600 mg Subcutaneous